101 |
Study on Propulsive Characteristics of Magnetic Sail and Magneto Plasma Sail by Plasma Particle Simulations / 粒子シミュレーションによる磁気セイル・磁気プラズマセイルの推力特性に関する研究Ashida, Yasumasa 23 January 2014 (has links)
京都大学 / 0048 / 新制・課程博士 / 博士(工学) / 甲第17984号 / 工博第3813号 / 新制||工||1584(附属図書館) / 80828 / 京都大学大学院工学研究科電気工学専攻 / (主査)教授 山川 宏, 教授 松尾 哲司, 准教授 中村 武恒 / 学位規則第4条第1項該当 / Doctor of Philosophy (Engineering) / Kyoto University / DFAM
|
102 |
Direction-sensitive dark matter search with a gaseous micro time projection chamber / 微細構造を用いた三次元ガス飛跡検出器による方向に感度を持つ暗黒物質探索実験Nakamura, Kiseki 24 March 2014 (has links)
京都大学 / 0048 / 新制・課程博士 / 博士(理学) / 甲第18074号 / 理博第3952号 / 新制||理||1569(附属図書館) / 30932 / 京都大学大学院理学研究科物理学・宇宙物理学専攻 / (主査)教授 谷森 達, 教授 鶴 剛, 准教授 市川 温子 / 学位規則第4条第1項該当 / Doctor of Science / Kyoto University / DFAM
|
103 |
Simulation Study on an Electron-Tracking Compton Camera for Deep Gamma-ray Burst Search / 電子飛跡検出型コンプトンカメラシミュレーションによるガンマ線バースト深探査Sawano, Tatsuya 23 March 2017 (has links)
京都大学 / 0048 / 新制・課程博士 / 博士(理学) / 甲第20172号 / 理博第4257号 / 新制||理||1612(附属図書館) / 京都大学大学院理学研究科物理学・宇宙物理学専攻 / (主査)教授 谷森 達, 教授 永江 知文, 教授 鶴 剛 / 学位規則第4条第1項該当 / Doctor of Science / Kyoto University / DGAM
|
104 |
Steps in the Development of a Full Particle-in-Cell, Monte Carlo Simulation of the Plasma in the Discharge Chamber of an Ion EnginePenkal, Bryan James 15 May 2013 (has links)
No description available.
|
105 |
Testing of Two Novel Semi-Implicit Particle-In-Cell TechniquesGodar, Trenton J. 05 August 2014 (has links)
No description available.
|
106 |
Performance Analysis of MC-CDMA and CI/MC-CDMA Using Interference Cancellation TechniquesSHARMA, ANSHUL 19 September 2008 (has links)
No description available.
|
107 |
Improved Statistical Interference Suppression Techniques in Single and Multi-rate Direct Sequence Spread Spectrum Code Division Multiple Access SystemsWang, Beibei 20 April 2007 (has links)
No description available.
|
108 |
Time-Domain Solvers for Complex-Media Electrodynamics and Plasma PhysicsDonderici, Burkay 10 September 2008 (has links)
No description available.
|
109 |
Experimental and Simulation Studies of Femtosecond Laser Stimulated Electrical Discharges in Small Gaps and Surface ModificationsChen, Jian January 2009 (has links)
No description available.
|
110 |
In vitro Performance Assessment of Recent Nebuliser Delivery Systems for Nebulisation of Approved Aerosolised Tobramycin (TOBI)®Mashat, M., Clark, Brian J., Assi, Khaled H., Chrystyn, Henry 31 December 2015 (has links)
Yes / TOBI® is a recently marketed preservative and sulphate free tobramycin formulation approved by FDA for
maintenance therapy for patient with cystic fibrosis. The performance of selected recent nebuliser delivery systems has
been assessed using the developed method to determine the optimum combinations to deliver approved tobramycin
inhaled solution (TOBI)®. A simple, sensitive and specific high performance liquid chromatographic method has been
developed and used to quantitative determination of the aminoglycoside tobramycin following pre-column derivatisation
with phenylisocyanate (PIC). The reaction time was 10 min at 80º C and the resulting derivative was stable for five days
at room temperature. The quantitative performance of the assay was further improved by using another aminoglycoside
(neomycin) as internal standard. The stable resulting PIC-tobramycin derivative was separated using a HPLC 5μm
Columbus C18 column (150x4.60 mm i.d, Phenomenex). The mobile phase was consisted of acetonitrile-glacial acetic
acid-water (450:5:545, v/v/v) and ultraviolet detection at (240 nm). The proposed method showed good validation data.
The standard curve was linear (n=5) at seven different concentrations, ranging from 20 to 140μg/ml and the correlation
coefficient (R2) of the regression line was 0.9995. The limit of detection (LOD) and limit of quantitation (LOQ) were
0.86μg/ml and 2.62μg/ml, respectively. The relative standard deviation (RSD %) was less than 0.6% for intra-day assay
(n=5) and 2.5% for inter-day assay (n=5). A number of nebuliser performance comparison studies have been
demonstrated for aerosolise TOBI® to choice the optimum combination produces high repirable inhaled mass of
tobramycin. The objective of this study was to evaluate the performance of recent nebuliser delivery systems to nebulise
approved tobramycin inhaled solution (TOBI)®.
|
Page generated in 0.026 seconds